The report involved motor neuropathy in a participant of the phase 2 trial conducted outside the U.S., according to an Oct. 16 news release from the company. The participant received the vaccine in ...
has lifted the clinicalhold on the investigational new drug application for the Phase 1 clinical trial evaluating OCU200, a recombinant fusion protein consisting of tumstatin and transferrin, ...